Regeneron Says Eylea HD Sustains Vision Gains in Diabetic Macular Edema in Extension Study
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Express News | Three-Year Results for Eylea Hd® (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements With Extended Dosing Intervals in Patients With Diabetic Macular Edema
Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $1,205 From $1,245
Here's What to Expect From Regeneron Pharmaceuticals' Next Earnings Report
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,137